{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T07:16:23Z","timestamp":1794467783260,"version":"4.9.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T00:00:00Z","timestamp":1691712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T00:00:00Z","timestamp":1691712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Empagliflozin reduces the risk of cardiovascular disease (CVD) in patients with type 2 diabetes (T2DM) and high cardiovascular risk via mechanisms which have not been fully explained. The mechanisms of such benefit have not been fully understood, and whether empagliflozin can be safely administered as first-line treatment in patients with CVD at the initial stages of glycaemic perturbations remains to be established. We investigated the effects of empagliflozin on insulin resistance, insulin sensitivity and \u03b2-cell function indexes in patients with a recent acute coronary event and newly detected dysglycaemia, i.e., impaired glucose tolerance (IGT) or T2DM.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Forty-two patients (mean age 67.5 years, 19% females) with a recent myocardial infarction (n\u2009=\u200936) or unstable angina (n\u2009=\u20096) and newly detected dysglycaemia were randomized to either empagliflozin 25\u00a0mg daily (n\u2009=\u200920) or placebo (n\u2009=\u200922). Patients were investigated with stress-perfusion cardiac magnetic resonance imaging before randomization, 7 months after the start of study drug and 3 months following its cessation. Indexes of insulin resistance, sensitivity and \u03b2-cell function were calculated based on glucose and insulin values from 2-hour oral glucose tolerance tests (OGTT) and fasting C-peptide. The differences in glucose, insulin, C-peptide, mannose levels and indexes between the two groups were computed by repeated measures ANOVA including an interaction term between the treatment allocation and the time of visit.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>After 7 months, empagliflozin significantly decreased glucose and insulin values during the OGTT, whereas C-peptide, mannose and HbA1c did not differ. Empagliflozin significantly improved insulin sensitivity indexes but did not impact insulin resistance and \u03b2-cell function. After cessation of the drug, all indexes returned to initial levels. Insulin sensitivity indexes were inversely correlated with left ventricular mass at baseline.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Empagliflozin improved insulin sensitivity indexes in patients with a recent coronary event and drug na\u00efve dysglycaemia. These findings support the safe use of empagliflozin as first-line glucose-lowering treatment in patients at very high cardiovascular risk with newly diagnosed dysglycaemia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration number<\/jats:title>\n                <jats:p>EudraCT number 2015-004571-73.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-023-01950-0","type":"journal-article","created":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T16:02:18Z","timestamp":1691769738000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Empagliflozin improves insulin sensitivity in patients with recent acute coronary syndrome and newly detected dysglycaemia"],"prefix":"10.1186","volume":"22","author":[{"given":"Elena","family":"Fortin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Lundin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Mellbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Norhammar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"N\u00e4sman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stina","family":"Smetana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peder","family":"S\u00f6rensson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ele","family":"Ferrannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Ryd\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Ferrannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,11]]},"reference":[{"issue":"5","key":"1950_CR1","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.2337\/dc05-2179","volume":"29","author":"MA Abdul-Ghani","year":"2006","unstructured":"Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care. 2006;29(5):1130\u20139.","journal-title":"Diabetes Care"},{"key":"1950_CR2","doi-asserted-by":"crossref","unstructured":"Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zu\u00f1iga FA. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol 2018, 17(1).","DOI":"10.1186\/s12933-018-0762-4"},{"issue":"20","key":"1950_CR3","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1161\/CIRCULATIONAHA.117.027952","volume":"135","author":"L Ryd\u00e9n","year":"2017","unstructured":"Ryd\u00e9n L, Mellbin L. New Hope for People with Dysglycemia and Cardiovascular Disease Manifestations. Circulation. 2017;135(20):1894\u20136.","journal-title":"Circulation"},{"issue":"1","key":"1950_CR4","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12933-021-01385-5","volume":"20","author":"A Natali","year":"2021","unstructured":"Natali A, Nesti L, Trico D, Ferrannini E. Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence. Cardiovasc Diabetol. 2021;20(1):196.","journal-title":"Cardiovasc Diabetol"},{"issue":"11","key":"1950_CR5","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1161\/CIRCULATIONAHA.122.060402","volume":"146","author":"S Selvaraj","year":"2022","unstructured":"Selvaraj S, Fu Z, Jones P, Kwee LC, Windsor SL, Ilkayeva O, Newgard CB, Margulies KB, Husain M, Inzucchi SE, et al. Metabolomic profiling of the Effects of Dapagliflozin in Heart failure with reduced ejection fraction: DEFINE-HF. Circulation. 2022;146(11):808\u201318.","journal-title":"Circulation"},{"issue":"3","key":"1950_CR6","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s10741-021-10096-8","volume":"27","author":"X Wang","year":"2022","unstructured":"Wang X, Ni J, Guo R, Li L, Su J, He F, Fan G. SGLT2 inhibitors break the vicious circle between heart failure and insulin resistance: targeting energy metabolism. Heart Fail Rev. 2022;27(3):961\u201380.","journal-title":"Heart Fail Rev"},{"issue":"2","key":"1950_CR7","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1172\/JCI72227","volume":"124","author":"E Ferrannini","year":"2014","unstructured":"Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T, Broedl UC, Woerle HJ. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124(2):499\u2013508.","journal-title":"J Clin Invest"},{"issue":"3","key":"1950_CR8","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/1753-0407.12494","volume":"9","author":"H Kaneto","year":"2017","unstructured":"Kaneto H, Obata A, Kimura T, Shimoda M, Okauchi S, Shimo N, Matsuoka T-A, Kaku K. Beneficial effects of sodium-glucose cotransporter 2 inhibitors for preservation of pancreatic < b > \u03b2 -cell function and reduction of insulin resistance. J Diabetes. 2017;9(3):219\u201325.","journal-title":"J Diabetes"},{"issue":"8","key":"1950_CR9","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1055\/a-0664-7583","volume":"128","author":"AM Ram\u00edrez-Rodr\u00edguez","year":"2020","unstructured":"Ram\u00edrez-Rodr\u00edguez AM, Gonz\u00e1lez-Ortiz M, Mart\u00ednez-Abundis E. Effect of dapagliflozin on insulin secretion and insulin sensitivity in patients with Prediabetes. Exp Clin Endocrinol Diabetes. 2020;128(8):506\u201311.","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"9","key":"1950_CR10","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.2337\/db17-0055","volume":"66","author":"M Abdul-Ghani","year":"2017","unstructured":"Abdul-Ghani M, Al Jobori H, Daniele G, Adams J, Cersosimo E, Triplitt C, Defronzo RA. Inhibition of renal sodium\u2013glucose Cotransport with Empagliflozin lowers fasting plasma glucose and improves \u03b2-Cell function in subjects with impaired fasting glucose. Diabetes. 2017;66(9):2495\u2013502.","journal-title":"Diabetes"},{"key":"1950_CR11","doi-asserted-by":"publisher","first-page":"110141","DOI":"10.1016\/j.diabres.2022.110141","volume":"193","author":"M Lundin","year":"2022","unstructured":"Lundin M, Ferrannini G, Mellbin L, Johansson I, Norhammar A, Nasman P, Shahim B, Smetana S, Venkateshvaran A, Wang A, et al. SOdium-glucose CO-transporter inhibition in patients with newly detected glucose abnormalities and a recent myocardial infarction (SOCOGAMI). Diabetes Res Clin Pract. 2022;193:110141.","journal-title":"Diabetes Res Clin Pract"},{"issue":"16","key":"1950_CR12","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1161\/CIR.0b013e31826e1058","volume":"126","author":"K Thygesen","year":"2012","unstructured":"Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Joint ESCAAHAWHFTFftUDoMI, Katus HA, Lindahl B, Morrow DA, et al. Third universal definition of myocardial infarction. Circulation. 2012;126(16):2020\u201335.","journal-title":"Circulation"},{"key":"1950_CR13","unstructured":"World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO\/IDF consultation. 2020. Accessed on 11 October 2022. [https:\/\/www.who.int\/publications\/i\/item\/definition-and-diagnosis-of-diabetes-mellitus-and-intermediate-hyperglycaemia]."},{"issue":"10","key":"1950_CR14","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1089\/dia.2014.0354","volume":"17","author":"E Segerhag","year":"2015","unstructured":"Segerhag E, Gyberg V, Ioannides K, Jennings C, Ryden L, Stagmo M, Hage C. Accuracy of a simplified glucose measurement device\u2013the HemoCue glucose 201RT. Diabetes Technol Ther. 2015;17(10):755\u20138.","journal-title":"Diabetes Technol Ther"},{"key":"1950_CR15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.cca.2019.02.024","volume":"493","author":"B Campi","year":"2019","unstructured":"Campi B, Codini S, Bisoli N, Baldi S, Zucchi R, Ferrannini E, Saba A. Quantification of d-mannose in plasma: development and validation of a reliable and accurate HPLC-MS-MS method. Clin Chim Acta. 2019;493:31\u20135.","journal-title":"Clin Chim Acta"},{"issue":"19","key":"1950_CR16","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1161\/01.CIR.100.19.1992","volume":"100","author":"RJ Kim","year":"1999","unstructured":"Kim RJ, Fieno DS, Parrish TB, Harris K, Chen EL, Simonetti O, Bundy J, Finn JP, Klocke FJ, Judd RM. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation. 1999;100(19):1992\u20132002.","journal-title":"Circulation"},{"key":"1950_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2342-10-1","volume":"10","author":"E Heiberg","year":"2010","unstructured":"Heiberg E, Sjogren J, Ugander M, Carlsson M, Engblom H, Arheden H. Design and validation of segment\u2013freely available software for cardiovascular image analysis. BMC Med Imaging. 2010;10:1.","journal-title":"BMC Med Imaging"},{"issue":"6","key":"1950_CR18","doi-asserted-by":"publisher","first-page":"610","DOI":"10.2337\/diacare.13.6.610","volume":"13","author":"L Rossetti","year":"1990","unstructured":"Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care. 1990;13(6):610\u201330.","journal-title":"Diabetes Care"},{"issue":"1","key":"1950_CR19","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1038\/s41598-022-05704-y","volume":"12","author":"T Okura","year":"2022","unstructured":"Okura T, Fujioka Y, Nakamura R, Kitao S, Ito Y, Anno M, Matsumoto K, Shoji K, Matsuzawa K, Izawa S, et al. The sodium-glucose cotransporter 2 inhibitor ipragliflozin improves liver function and insulin resistance in japanese patients with type 2 diabetes. Sci Rep. 2022;12(1):1896.","journal-title":"Sci Rep"},{"issue":"5","key":"1950_CR20","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1210\/jc.2014-3472","volume":"100","author":"A Merovci","year":"2015","unstructured":"Merovci A, Mari A, Solis C, Xiong J, Daniele G, Chavez-Velazquez A, Tripathy D, Urban Mccarthy S, Abdul-Ghani M, Defronzo RA. Dapagliflozin lowers plasma glucose concentration and improves \u03b2-Cell function. J Clin Endocrinol Metabolism. 2015;100(5):1927\u201332.","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"1","key":"1950_CR21","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1507\/endocrj.EJ14-0335","volume":"62","author":"M Takahara","year":"2015","unstructured":"Takahara M, Shiraiwa T, Matsuoka T-A, Katakami N, Shimomura I. Ameliorated pancreatic \u03b2 cell dysfunction in type 2 diabetic patients treated with a sodium-glucose cotransporter 2 inhibitor ipragliflozin. Endocr J. 2015;62(1):77\u201386.","journal-title":"Endocr J"},{"issue":"8","key":"1950_CR22","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1111\/dom.12923","volume":"19","author":"CN Joannides","year":"2017","unstructured":"Joannides CN, Mangiafico SP, Waters MF, Lamont BJ, Andrikopoulos S. Dapagliflozin improves insulin resistance and glucose intolerance in a novel transgenic rat model of chronic glucose overproduction and glucose toxicity. Diabetes Obes Metabolism. 2017;19(8):1135\u201346.","journal-title":"Diabetes Obes Metabolism"},{"issue":"9467","key":"1950_CR23","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/S0140-6736(05)61032-X","volume":"365","author":"M Stumvoll","year":"2005","unstructured":"Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 2005;365(9467):1333\u201346.","journal-title":"Lancet"},{"issue":"1","key":"1950_CR24","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12933-022-01630-5","volume":"21","author":"E Fortin","year":"2022","unstructured":"Fortin E, Ferrannini G, Campi B, Mellbin L, Norhammar A, Nasman P, Saba A, Ferrannini E, Ryden L. Plasma mannose as a novel marker of myocardial infarction across different glycaemic states: a case control study. Cardiovasc Diabetol. 2022;21(1):195.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1950_CR25","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.cmet.2016.05.026","volume":"24","author":"S Lee","year":"2016","unstructured":"Lee S, Zhang C, Kilicarslan M, Piening BD, Bjornson E, Hallstrom BM, Groen AK, Ferrannini E, Laakso M, Snyder M, et al. Integrated Network Analysis reveals an association between plasma mannose levels and insulin resistance. Cell Metab. 2016;24(1):172\u201384.","journal-title":"Cell Metab"},{"issue":"16","key":"1950_CR26","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1016\/j.jacc.2021.02.057","volume":"77","author":"H Honka","year":"2021","unstructured":"Honka H, Solis-Herrera C, Triplitt C, Norton L, Butler J, DeFronzo RA. Therapeutic manipulation of myocardial metabolism: JACC state-of-the-art review. J Am Coll Cardiol. 2021;77(16):2022\u201339.","journal-title":"J Am Coll Cardiol"},{"key":"1950_CR27","doi-asserted-by":"publisher","first-page":"155396","DOI":"10.1016\/j.metabol.2022.155396","volume":"140","author":"A Veelen","year":"2023","unstructured":"Veelen A, Andriessen C, Op den Kamp Y, Erazo-Tapia E, de Ligt M, Mevenkamp J, Jorgensen JA, Moonen-Kornips E, Schaart G, Esterline R, et al. Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on substrate metabolism in prediabetic insulin resistant individuals: a randomized, double-blind crossover trial. Metabolism. 2023;140:155396.","journal-title":"Metabolism"},{"issue":"14","key":"1950_CR28","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","volume":"374","author":"WN Kernan","year":"2016","unstructured":"Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, Guarino PD, Lovejoy AM, Peduzzi PN, Conwit R, et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 2016;374(14):1321\u201331.","journal-title":"N Engl J Med"},{"issue":"9493","key":"1950_CR29","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","volume":"366","author":"JA Dormandy","year":"2005","unstructured":"Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in macroVascular events): a randomised controlled trial. Lancet. 2005;366(9493):1279\u201389.","journal-title":"Lancet"},{"issue":"6","key":"1950_CR30","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/S2213-8587(14)70057-9","volume":"2","author":"G Li","year":"2014","unstructured":"Li G, Zhang P, Wang J, An Y, Gong Q, Gregg EW, Yang W, Zhang B, Shuai Y, Hong J, et al. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing diabetes Prevention Study: a 23-year follow-up study. Lancet Diabetes Endocrinol. 2014;2(6):474\u201380.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"21","key":"1950_CR31","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","volume":"140","author":"S Verma","year":"2019","unstructured":"Verma S, Mazer CD, Yan AT, Mason T, Garg V, Teoh H, Zuo F, Quan A, Farkouh ME, Fitchett DH, et al. Effect of Empagliflozin on Left Ventricular Mass in patients with type 2 diabetes Mellitus and Coronary Artery Disease: the EMPA-HEART CardioLink-6 Randomized Clinical Trial. Circulation. 2019;140(21):1693\u2013702.","journal-title":"Circulation"},{"issue":"9","key":"1950_CR32","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.2337\/dc17-0245","volume":"40","author":"B Shahim","year":"2017","unstructured":"Shahim B, De Bacquer D, De Backer G, Gyberg V, Kotseva K, Mellbin L, Schnell O, Tuomilehto J, Wood D, Ryden L. The Prognostic Value of Fasting plasma glucose, two-hour postload glucose, and HbA1c in patients with coronary artery disease: a Report from EUROASPIRE IV: a Survey from the European Society of Cardiology. Diabetes Care. 2017;40(9):1233\u201340.","journal-title":"Diabetes Care"},{"issue":"2","key":"1950_CR33","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1002\/ehf2.13805","volume":"9","author":"AK Pandey","year":"2022","unstructured":"Pandey AK, Dhingra NK, Hibino M, Gupta V, Verma S. Sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a meta-analysis. ESC Heart Fail. 2022;9(2):942\u20136.","journal-title":"ESC Heart Fail"},{"issue":"2","key":"1950_CR34","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"F Cosentino","year":"2020","unstructured":"Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, Federici M, Filippatos G, Grobbee DE, Hansen TB, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255\u2013323.","journal-title":"Eur Heart J"},{"issue":"1","key":"1950_CR35","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1210\/js.2018-00206","volume":"3","author":"R Muniyappa","year":"2019","unstructured":"Muniyappa R, Tella SH, Sortur S, Mszar R, Grewal S, Abel BS, Auh S, Chang DC, Krakoff J, Skarulis MC. Predictive accuracy of surrogate indices for hepatic and skeletal muscle insulin sensitivity. J Endocr Soc. 2019;3(1):108\u201318.","journal-title":"J Endocr Soc"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-023-01950-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-023-01950-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-023-01950-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T02:22:33Z","timestamp":1700533353000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-023-01950-0"}},"subtitle":["Experiences from the randomized, controlled SOCOGAMI trial"],"short-title":[],"issued":{"date-parts":[[2023,8,11]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1950"],"URL":"https:\/\/doi.org\/10.1186\/s12933-023-01950-0","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,11]]},"assertion":[{"value":"19 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients signed consent to study participation following written and oral information. The study was conducted in compliance with principles in the Declaration of Helsinki, 1996 version, as well as in accordance with the ICH Harmonized Tripartite Guideline for Good Clinical Practice and applicable regulatory requirements. The protocol was approved by the Regional Ethics committee in Stockholm (Dnr 2015:4\/11) and the trial is registered in the European Union Drug Regulating Authorities Clinical Trials Database (EudraCT) with the number 2015-004571-73. The funder had no role in design and conduct of the trial.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"ML: has no conflicts of interest related to this work.LM: has no conflicts of interest related to this work.AN: has received research grants from the Swedish Heart-Lung Foundation and honoraria for lectures and consulting from Astra Zeneca, Boehringer-Ingelheim, Novo Nordisk.PN: has no conflicts of interest related to this work.SS: has no conflicts of interest related to this work.PS: has no conflicts of interest related to this work.E. Ferrannini: has no conflicts of interest related to this work.LR: has received research grants from the Swedish Heart-Lung Foundation, Erling Perssons Foundation, Region Stockholm (ALF), Boehringer-Ingelheim and honoraria for lectures and consulting from Bayer, Boehringer-Ingelheim, Novo Nordisk.GF: has no conflicts of interest related to this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"208"}}